Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Enzolinion May 06, 2019 11:25am

92 Views

Post# 29714797

RE:My two cents

So sad but true!!!!! It's a crazy cycle, company will luer new investor while us old investors sit back and watch the sp tumble and listen to the CEO state BS about Partnerships and now BS about getting into the cbd market. He will say anything to get new money in. While he's probably selling all his shares some how. Yes I lost money here and thats why I'm bitter about this company but hopefully other people dont follow in my footsteps. I wouldn't be surpized if the person behind the FB group is geting paid to post BS since "this company can't even promote itself". So to peple looking to invest STAY AWAY, or lose your investment like all of us!!

Bullboard Posts

Transportation technology stock secures second major contract in a week